The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | MAVORIC: long-term clinical benefit of mogamulizumab in patients with CTCL
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, presents results from post hoc analyses of the MAVORIC trial (NCT01728805), a Phase III study evaluating mogamulizumab versus vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). Follow-up studies indicated that long-term responses were not associated with new side effects. In addition, a subset of patients is still in partial or complete response after long-term treatment with mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
